Evidence for efficacy is based on the results from the CADENZA study
Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.
ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH
© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer | 5 | 5 | 08-07-2026 |
| 2 | FDA accepts cemdisiran for priority review as gMG treatment | 2 | 6 | 07-07-2026 |
| 3 | FDA approves gene therapy for children with sickle cell disease ages 2+ | 5 | 7 | 09-07-2026 |
| 4 | EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan | 0 | 5 | 10-07-2026 |
| 5 | FDA Approves Trodelvy — A Breakthrough Treatment For One Of The Deadliest Breast Cancers | 8 | 7 | 30-06-2026 |
| 6 | В РФ поступила первая партия швейцарского препарата для лечения гемофилии с маркировкой | 0 | 0 | 02-06-2020 |
| 7 | Дефицит препарата "Винкристин" в России ликвидируют в ближайшие дни | 0 | 0 | 09-11-2020 |
| 8 | В РФ готовят к выпуску первый отечественный препарат против онкозаболевания крови | 0 | 0 | 25-04-2025 |
| 9 | Минздрав одобрил применение первого отечественного препарата для лечения меланомы | 0 | 0 | 20-04-2020 |
| 10 | New approach to gene correction for iron storage disease | 2 | 7 | 09-07-2026 |